KR101672138B1 - Composition comprising Cudraflavanone D or Steppogenin isolated from Cudrania tricuspidata as a standard for the preventing and treating of inflammatory diseases - Google Patents
Composition comprising Cudraflavanone D or Steppogenin isolated from Cudrania tricuspidata as a standard for the preventing and treating of inflammatory diseases Download PDFInfo
- Publication number
- KR101672138B1 KR101672138B1 KR1020150106965A KR20150106965A KR101672138B1 KR 101672138 B1 KR101672138 B1 KR 101672138B1 KR 1020150106965 A KR1020150106965 A KR 1020150106965A KR 20150106965 A KR20150106965 A KR 20150106965A KR 101672138 B1 KR101672138 B1 KR 101672138B1
- Authority
- KR
- South Korea
- Prior art keywords
- disease
- steppogenin
- cudraflavanone
- inflammatory
- cells
- Prior art date
Links
- QBLQLKNOKUHRCH-CYBMUJFWSA-N Norartocarpanone Natural products OC1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 QBLQLKNOKUHRCH-CYBMUJFWSA-N 0.000 title claims abstract description 18
- DIDKWDDDUNDCBA-UHFFFAOYSA-N steppogenin Natural products Oc1ccc(C2CCc3c(O)cc(O)cc3O2)c(O)c1 DIDKWDDDUNDCBA-UHFFFAOYSA-N 0.000 title claims abstract description 18
- XLHAGJGNSIEVFB-UHFFFAOYSA-N euchrestaflavanone B Natural products C1=C(O)C(CC=C(C)C)=CC(C2OC3=CC(O)=C(CC=C(C)C)C(O)=C3C(=O)C2)=C1O XLHAGJGNSIEVFB-UHFFFAOYSA-N 0.000 title claims abstract description 17
- QBLQLKNOKUHRCH-ZDUSSCGKSA-N (2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one Chemical compound OC1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 QBLQLKNOKUHRCH-ZDUSSCGKSA-N 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 title description 27
- 208000027866 inflammatory disease Diseases 0.000 title description 7
- 235000010918 Cudrania tricuspidata Nutrition 0.000 title 1
- 241001523380 Maclura tricuspidata Species 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 230000037361 pathway Effects 0.000 claims abstract description 21
- 206010061218 Inflammation Diseases 0.000 claims abstract description 18
- 230000004054 inflammatory process Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 14
- -1 Steppogenin compound Chemical class 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000002036 chloroform fraction Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000401 methanolic extract Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010003694 Atrophy Diseases 0.000 claims description 5
- 208000014644 Brain disease Diseases 0.000 claims description 5
- 208000032274 Encephalopathy Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 230000037444 atrophy Effects 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000014311 Cushing syndrome Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 41
- 102000043136 MAP kinase family Human genes 0.000 abstract description 18
- 108091054455 MAP kinase family Proteins 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 210000000274 microglia Anatomy 0.000 abstract description 16
- 230000002757 inflammatory effect Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 239000003623 enhancer Substances 0.000 abstract description 3
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 26
- 229920006008 lipopolysaccharide Polymers 0.000 description 26
- 230000005764 inhibitory process Effects 0.000 description 25
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 19
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 12
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 12
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 12
- 102000005747 Transcription Factor RelA Human genes 0.000 description 12
- 108010031154 Transcription Factor RelA Proteins 0.000 description 12
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 11
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000002265 prevention Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000028709 inflammatory response Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 229910002091 carbon monoxide Inorganic materials 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 108010006401 NF-kappa B p50 Subunit Proteins 0.000 description 6
- 102000005395 NF-kappa B p50 Subunit Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000002025 microglial effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102100035100 Transcription factor p65 Human genes 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000037426 transcriptional repression Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 240000008067 Cucumis sativus Species 0.000 description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000003293 Magnolia grandiflora Species 0.000 description 2
- 235000008512 Magnolia grandiflora Nutrition 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000005550 inflammation mediator Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- YPWHZCPMOQGCDQ-HMGRVEAOSA-N kaempferol 7-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-HMGRVEAOSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- JRXXLCKWQFKACW-UHFFFAOYSA-N biphenylacetylene Chemical compound C1=CC=CC=C1C#CC1=CC=CC=C1 JRXXLCKWQFKACW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000954 inflammatory inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002264 mitodepressive effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The Cudraflavanone D and steppogenin of the present invention are compounds isolated from cucurbitaceous trees. In the present invention, it was confirmed that the coadaplavanone D and stepojenin were excellent in the effect of inhibiting inflammation in mouse-derived microglia, BV2 cells, and thus the inhibitory effect of inflammatory mediators was also apparent. The anti-inflammatory effects of the copla-laparavone D and stepojenin are known to be related to the nuclear factor kappa-light-chain-enhancer of activated B (NF-kB) and mitogen- activated protein kinase pathway. Cudrabravanone D and stepogensin inhibited the overexpression of NF-kB and MAPK pathway, and thus showed excellent anti-inflammatory effects.
Description
The present invention relates to a composition for treating and preventing an inflammatory disease, which comprises a compound isolated from Curdrania tricuspidata as an active ingredient, and more particularly, to a composition for treating or preventing inflammatory diseases comprising Cudraflavanone D or Cudraflavanone D The present invention relates to a pharmaceutical composition and a health functional food for the prevention and treatment of microglia cell-associated inflammatory diseases containing steppogenin as an active ingredient.
Inflammation is caused by harmful substances or damage by chemical stimulation before the body's defense against external stimuli. When an inflammatory reaction occurs, inflammatory mediators are created, leading to symptoms such as fever, fever, swelling, pain, and dysfunction. In addition to activating the oxidative stress transcription factor nuclear factor kappa-b (NF-κB), reactive oxygen species generated from the inflammatory reaction are also important signal transducer inducible nitric oxide synthase (iNOS) and inflammatory inducer cyclooxygenase (COX-2), thereby promoting the inflammatory response, leading to abnormal mutations and cancer.
Microglial cells play a central role in the inflammatory response in the central nervous system involved in various neuropathic diseases. In the present invention, a molecular microphysiological study on the inflammatory response induced by LPS, a compound isolated from cucurbitan tree, Cudraflavanone D or steppogenin, was studied using a microglial cell model .
Curdrania tricuspidata is a deciduous broad-leaved arboreous tree belonging to the genus Molaceae. It is distributed mainly in East Asia including Korea, and 10 species are known. In Korea, only one species is native, and morin papulinin ), Stachydrine, kaempferol-7-glucoside, and the like.
However, no studies have been reported on the effects of Cudraflavanone D and Steppogenin on microglial cells associated with inflammatory diseases in the literature.
In this invention, Cudraflavanone D and Steppogenin isolated from Cucumber japonica have excellent effect of inhibiting inflammation in mouse-derived microglia, BV2 cells, and thus the inflammatory mediator The inhibitory effect was also evident. The anti-inflammatory effects of the copla-laparavone D and stepojenin are known to be related to the nuclear factor kappa-light-chain-enhancer of activated B (NF-kB) and mitogen- activated protein kinase pathway. Cudrabravanone D and stepogenin inhibit the activity of overexpressed NF-kB and MAPK pathway, confirming that the anti-inflammatory effect is excellent, and thus a composition and a composition for prevention and treatment of microglial cell- And thus the present invention has been completed.
Related prior arts are Korean Patent No. 10-0701607 entitled " Composition for prevention and treatment of cancer containing quadruplavanone A separated from cucumber tree having inhibitory activity of topoisomerase I "and Korean Patent No. 10 -1355821 "A composition for the prevention and treatment of alcoholic gastrointestinal tract diseases containing an extract of Cedarwood bean as an active ingredient ".
The present invention provides a pharmaceutical composition and a health functional food for the prevention and treatment of anti-inflammatory, which comprises as an active ingredient coudraplavanone D or stepogensin, which is a compound isolated from cheddar.
The present invention provides a pharmaceutical composition for the prevention and treatment of anti-inflammatory activity comprising Cudraflavanone D or Steppogenin compound isolated from Curdrania tricuspidata as an active ingredient.
The compound is obtained by extracting Curdrania tricuspidata with methanol; Dissolving the methanol extract in water and obtaining a chloroform fraction using a solution-solution dispensing method with chloroform; And separating the chloroform fraction through fractionation using silica gel column chromatography.
The anti-inflammatory agent is characterized in that it is at least one selected from the group consisting of Lou Gehrig's disease, Parkinson's disease, Huntington's disease, Alzheimer's disease, multiple sclerosis, multiple nervous atrophy, epilepsy, encephalopathy and stroke.
The inflammation-inhibiting pathway of the Cudraflavanone D or Steppogenin compound is characterized by inhibiting the p-JNK or p-38 pathway.
In addition, the present invention provides a health functional food for preventing and improving anti-inflammation comprising Cudraflavanone D or Steppogenin compound isolated from Curdrania tricuspidata as an active ingredient.
The present invention relates to an anti-inflammatory effect which comprises quadruplavanone D or stepogenin, which is isolated from cucurbitaceous tree, as an active ingredient. Cucurbitan is a natural resource and has excellent cytotoxicity, The compounds of the present invention are useful as pharmaceutical compositions and health functional foods for the prevention and treatment of various inflammatory diseases by inhibiting the pathway of factors important for inflammatory reaction and having an anti-inflammatory effect.
FIG. 1 is a view showing a method of separating codaplavanone D or stepojenin from Coleoptera.
FIG. 2 is a diagram showing the structure of coudraplavanone D, showing the structure identification (A) and 13 C-NMR (B) by 1 H-NMR and the structure identification (C).
FIG. 3 is a graph showing the cell survival rate for evaluating cytotoxicity of cupraflavanone D. FIG.
FIG. 4 is a graph showing the inhibitory effect of TNF-α (A), IL-1β (B), IL-12 (C) and IL-6 (D) mRNAs on the inflammatory cytokines of coadaplavanone D.
5 is a graph showing the effect of suppressing (C) the NO production inhibitory effect (A), the PGE 2 generation inhibitory effect (B), and the iNOS and COX-2 protein expression levels of cupraflavavanone D.
Figure 6 shows the effect (A) of inhibiting IκB-α degradation and phosphorylated IκB-α in the cytoplasmic fraction of codraprapavanone D, the transcriptional repression inhibition of NF-kB p65 and p50 in the cytoplasmic fraction (B) (E) suppresses the transcriptional repression inhibitory effect of p65 and p50 (C), the transcriptional repression inhibitory effect of p50 on the nucleus by immunofluorescence staining (D), and the binding activity of NF-kB in the nuclear fraction Fig.
7 is a graph showing an inhibitory effect on the mitogen activated protein kinase (MAPKs) activity pathway ERK (A), JNK (B), and p38 (C) of codaplavanone D. FIG.
FIG. 8 is a diagram showing the structure of steppenine. FIG. 12A shows structure identification by 1 H-NMR, FIG. 13B shows structure identification by 13 C-NMR, and FIG.
FIG. 9 is a graph showing cell viability to examine cytotoxicity of stepojenin. FIG.
FIG. 10 is a graph showing the inhibitory effect of steppenine on inflammatory cytokines TNF-α (A), IL-1β (B), IL-12 (C) and IL-6 (D) mRNA.
Fig. 11 is a graph showing the effect of inhibiting NO production (step A) of stephenin, the effect of inhibiting PGE 2 production, and the inhibitory effect (C) of iNOS and COX-2 protein expression.
Figure 12 shows the effect of inhibiting IκB-α degradation and phosphorylated IκB-α in the cytoplasmic fraction of stepogenin (A), the inhibition of transcription of NF-kB p65 and p50 in the cytoplasmic fraction (B) (E) suppression of the transcriptional repression inhibitory effect (C) of p50, the suppression effect of transfer of p50 into the nucleus (D) by immunofluorescence staining, and the binding activity of NF-kB in nuclear fraction to be.
FIG. 13 is a graph showing inhibitory effects of steppenine on mitogen activated protein kinase (MAPKs) activation pathways ERK (A), JNK (B) and p38 (C).
The present invention provides a pharmaceutical composition for the prevention and treatment of anti-inflammation comprising Cudraflavanone D or Steppogenin as an active ingredient.
The Cudraflavanone D or Steppogenin of the present invention is characterized in that it is isolated from Curdrania tricuspidata, which is a deciduous broad-leaved tree of Morus alba.
The anti-inflammation defined in the present invention collectively refers to anti-inflammation occurring in microglial cells, and includes but is not limited to anti-inflammatory related to neuropathic diseases, preferably Lou SS, Parkinson's disease, Huntington's disease, Alzheimer's disease, Multiple sclerosis, multiple nervous atrophy, epilepsy, encephalopathy, and stroke.
The compounds of the present invention may be prepared into pharmaceutically acceptable salts and solvates by methods conventional in the art.
Pharmaceutically acceptable salts include acid addition salts formed by free acids. The acid addition salt is prepared by a conventional method, for example, by dissolving the compound in an excess amount of an acid aqueous solution, and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. The molar amount of the compound and the acid or alcohol (e.g., glycol monomethyl ether) in water may be heated and then the mixture may be evaporated to dryness, or the precipitated salt may be subjected to suction filtration.
As the free acid, organic acids and inorganic acids can be used. As the inorganic acids, hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid and the like can be used. Examples of the organic acids include methanesulfonic acid, p- toluenesulfonic acid, acetic acid, trifluoroacetic acid, Maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycollic acid, gluconic acid glutamic acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, and the like can be used.
In addition, bases can be used to make pharmaceutically acceptable metal salts. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the non-soluble compound salt, and evaporating and drying the filtrate. At this time, it is preferable for the metal salt to produce sodium, potassium or calcium salt in particular, and the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).
Pharmaceutically acceptable salts of the compounds of the present invention include, unless otherwise indicated, salts of acidic or basic groups that may be present in the compounds of the present invention. For example, pharmaceutically acceptable salts include the sodium, calcium and potassium salts of the hydroxy groups
Other pharmaceutically acceptable salts of amino groups include hydrobromide, sulphate, hydrogen sulphate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (Mesylate) and p-toluenesulfonate (tosylate) salts, which can be prepared by methods known to those skilled in the art or by the preparation of salts.
The present compounds of the present invention can be used for the treatment of lipopolysaccharide (LPS) -induced microglial cell damage. NF-kB (nuclear factor kappa-light-chain-enhancer of activated B) and mitogen-activated protein kinase (MAPK) pathway, thereby confirming that it can be effectively used as a pharmaceutical composition and a health functional food for the prevention and treatment of anti-inflammation.
The pharmaceutical composition for preventing and treating anti-inflammation of the present invention comprises 0.1 to 50% by weight of the above compound based on the total weight of the composition.
However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.
Since the compound itself of the present invention has little toxicity and side effects, it can be safely used for long-term use for preventive purposes.
The pharmaceutical compositions comprising the compounds of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
The composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition including the compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of liquid formulations for oral use include suspensions, solutions, emulsions, and syrups. Various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. may be included in addition to water and liquid paraffin which are simple diluents used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
The preferred dosage of the composition of the present invention can be determined in consideration of the condition and body weight of the patient, the degree of disease, the type of drug, the route of administration, and the absorbance, inactivity and the drug to be used in combination with the active ingredient in the body, (Body weight) to 500 mg / kg (body weight), 0.1 mg / kg (body weight) to 400 mg / kg (body weight) or 1 mg / kg (body weight) to 300 mg / kg (body weight), and may be administered once or several times in divided doses. The dose is not intended to limit the scope of the invention in any way. And may be suitably selected by those skilled in the art.
The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
In addition, the present invention provides a health functional food for preventing and improving anti-inflammation comprising a compound isolated from a tree as an active ingredient.
In addition, the present invention provides a food or food additive containing, as an active ingredient, a compound isolated from the above-mentioned Cucumber tree having the effect of preventing and improving neurological diseases.
The composition comprising the compound of the present invention can be used variously for medicines, foods and drinks for the prevention and improvement of neurological diseases.
Examples of foods to which the compound of the present invention can be added include various foods, beverages, gums, tea, vitamin complexes, health supplements and the like, and they can be used in powder, granule, tablet, have.
The compounds of the present invention can be added to foods or beverages for the purpose of preventing and improving neurological diseases. At this time, the amount of the compound in the food or beverage may generally be from 0.01 to 15% by weight of the total food weight of the health food composition of the present invention, and the health beverage composition is preferably 0.02 to 10 g based on 100 ml, Can be added at a ratio of 0.3 to 1 g.
The health beverage composition of the present invention contains the above-mentioned compound as an essential ingredient in the indicated ratio, and there is no particular limitation on the liquid ingredient, and the ordinary beverage can contain various flavors or natural carbohydrates as an additional ingredient. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose and sucrose and polysaccharides such as dextrin and sludge dextrin Conventional sugars and sugar alcohols such as xylitol, sorbitol, and erythritol. (Taurine, or stevia extract (for example, glycyrrhizin containing rebaudioside A) and synthetic flavors (saccharin, aspartame, etc.) as flavors other than the above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 mL of the composition of the present invention.
In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like.
In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention
Hereinafter, the present invention will be described in detail with reference to the following experimental examples.
However, the following experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following experimental examples.
Example One. From the cedarwood tree, D ( Cudraflavanone D)
A method for separating Cudraflavanone D is shown in FIG. As shown in FIG. 1, 300 g of a 100% methanol extract was obtained by allowing the cucumber (6 kg) to stand at room temperature for 24 hours in 100% methanol. The 100% methanol extract was dissolved in water, and 160 g of a chloroform fraction was obtained using a solution-solution partitioning method using chloroform. The resulting chloroform fractions were fractionated using silica gel CC column chromatography (20%, 40%, 60%, 80%, 100% (v / v) EtOAc in hexane) . Four fractions (45 g) were obtained by silica gel CC column chromatography using chloroform: ethyl acetate = 10: 1 ratio. Four fractions were separated by silica gel CC column chromatography using hexane: acetone = 5: 1, 4: 1, 3: 1, 2: . The second fraction thereof was subjected to RP 18 column chromatography to obtain 60 mg of coudraplavanone D using a methanol: water = 3: 1 ratio solvent.
In order to identify the structure of the obtained coudralavanone D, the structure was identified using 1 H-NMR of FIG. 2A and 13 C-NMR of FIG. 2B, and the results as shown in FIG. 2C were obtained.
brown oil. 1 H-NMR (MeOD, 400 MHz) δ 5.58 (dd, J = 3.2, 12.4 Hz, H-2), 3.03 (dd, J = 12.0, 17.2 Hz, H-3a), 2.71 (dd, J = 3.2 , 17.2 Hz, H-3b) , 5.93 (s, H-8), 6.32 (s, H-3 '), 7.03 (s, H-6'), 3.18 (d, J = 7.2 Hz, H-11 ), 5.18 (m, H- 12), 1.73 (s, H3-14), 1.65 (s, H3-15), 3.18 (d, J = 7.2 Hz, H-16), 5.25 (m, H-17 ), 1.63 (s, H3-19), 1.69 (s, H3-20). 13 C-NMR (MeOD, 100 MHz) δ 75.9 (C-2), 43.1 (C-3), 198.4 (C-4), 162.4 (C-5), 109.4 (C-6), 165.8 (C- (C-10), 117.5 (C-1 '), 154.3 (C-2'), 103.3 (C-3 '), 156.8 C-4 '), 120.5 (C-5'), 128.6 (C-6 '), 21.8 (C-11), 123.9 25.9 (C-15), 28.6 (C-16), 124.3 (C-17), 132.5 (C-18), 25.9 (C-19), 17.7 (C-20).
Experimental Example 1. Mouse-derived microglia, BV2 cell culture and cytotoxicity
Mouse microsomal BV2 cells (2 × 10 5 cells / well) were mixed with 10% heat-inactivated FBS, penicillin G (100 IU / ml, Gibco, 15240062) and streptomycin (100 μg / Gibco, 15240062), cultured in a 5% carbon dioxide incubator (Sanyo, MCO175) at 37 ° for 24 hours, treated with the concentration of codraprapavanone D for 48 hours, and cultured in a 5% CO 2 incubator And cell viability was measured using MTT method. In addition, all the experimental values were expressed as the average cell survival rate for the control group, and were calculated using the experiment values repeated three times.
In order to measure cytotoxicity, primary cultured macrophages (1.25, 2.5, 5, 10 μM), which was isolated from abdominal cavity of mice, were treated for 48 hours and cell viability was measured. As a result, D, the cell survival rate remained high regardless of the concentration (Fig. 3).
Experimental Example 2. Mouse-derived microglia BV2 cells Inhibitory effect of inflammatory cytokines TNF-α, IL-1β, IL-12, and IL-6 on mRNA expression
BV2 cells, which are mouse-derived microglia, were treated with 1.25, 2.5, 5, and 10 μM of Cdraplavanone D for 3 hours, followed by induction of inflammatory reaction with lipopolysaccharide (LPS) % CO2 incubator. As a result of the RT-PCR, TNF-α (FIG. 4A), IL-1β (FIG. 4B), IL-12 (FIG. 4C) 6 mRNA expression (Fig. 4D) was inhibited in a concentration-dependent manner when treated with 1.25, 2.5, 5, or 10 μM of codraprapavanone D.
Experimental Example 3. In BV2 cells, a mouse-derived microglia, inflammation mediators NO, PGE 2 , inhibitory effect of iNOS and COX-2 protein expression
To investigate the production of NO, PGE 2 and the inhibition of protein expression of iNOS and COX-2, which are inflammatory mediators in BV2 cells of cupraclavanone D, Kim et al., European Journal of Pharmacology, 721, pp. 267-276, 2013).
BV2 cells were pretreated with 1.25, 2.5, 5 and 10 μM of codraplavanone D for 3 hours, and then induced with inflammatory reaction with lipopolysaccharide (LPS) and cultured in a 5
Specifically, the western blot analysis was carried out in order to confirm the effect of the above-mentioned codraplavanone D and the treatment time to promote iNOS and COX-2 protein expression.
First, BV2 cells were cultured for 12 hours at a concentration of 3 × 10 6 cells / ml in a 60 mm dish, treated with lupopolysaccharide at a concentration of 1 μg / ml, treated with coudraplavanone D for 24 hours, . After the above cultivation, RIPA (89900, Thermo) buffer was added and the supernatant was separated by centrifugation at 4 DEG C and 14,000 X g for 25 minutes. Protein quantification in the supernatant was performed using a BSA protein kit (Pierce Biotechnology).
Specifically, the supernatant was subjected to electrophoresis for 2 hours using 7.5% SDS-polyacrylamide gel, and then transferred from the polyacrylamide gel using a nitrocellulose membrane (NC membrane) Respectively. The transferred nitrocellulose membrane was terminated in a blocking buffer (0.1
After the reaction, the plate was washed three times with PBST once every 10 minutes, and then mixed with ECL (Amersham Pharmacia Biotech) solution at a ratio of 1: 1 and poured on a nitrocellulose membrane (NC membrane) to emit light. The film was sensitized and developed. Actin content was measured in the same manner using an antibody against actin (SC-1616, Santacruz biotechnology, USA).
As shown in FIG. 5C, it was confirmed that the protein expression of iNOS and COX-2, which are known as inflammatory mediators, is significantly suppressed as the concentration of the copla laparavone D increases.
Experimental Example 4. Mouse-derived microglia in BV2 cells IκBα Decomposition inhibition, Iκ Inhibition of Bα phosphorylation, inhibition of NFκB (p65, p50) nuclear transfer and inhibition of NFκB p65 binding ability
We examined the effect of coadaplavanone D on the NFκB-related pathway in BV2 cells. To investigate inhibition of IκBα degradation, inhibition of IκBα phosphorylation, inhibition of NFκB p65 and p50 nuclear transfer, and inhibition of NFκB p65 binding ability, the method of the above-mentioned method (Kim et al., European Journal of Pharmacology, 721, pp. 267-276, The experiment was carried out using western blot analysis, which is the same method as in Experimental Example 3.
BV2 cells were treated with 2.5, 5, and 10 μM of Cudrablavanone D for 3 hours, followed by induction of the inflammatory response pathway with lipopolysaccharide, followed by incubation in a 5
Experimental Example In BV2 cells, a mouse-derived microglia, Mito Inhibitory effect of gene active protein kinase expression
Suppression of p-ERK, p-JNK, and p-38 expression, which are mitogen-activated protein kinase (MAPK) species, against inflammatory response induced by lipopolysaccharide in BV2 cells of Kudraplavanone D Using the method of Kim et al., European Journal of Pharmacology, 721, pp. 267-276, 2013 and Western blot analysis, which is the same method as in Experimental Example 3, Respectively.
BV2 cells were pretreated with 2.5, 5, 10 μM of Cudrablavanone D for 3 hours, and then cultured in a 5% CO 2 incubator for 1 hour with induction of inflammatory response pathway by lipopolysaccharide. As a result, the expression of p-ERK (Fig. 7A), p-JNK (Fig. 7B) and p-38 (Fig. 7C) was detected by lipopolysaccharide Respectively. However, the expression of p-JNK (Fig. 7B) and p-38 (Fig. 7C) was gradually decreased and the expression of p-ERK (Fig. 7A) was not changed. This indicates that the inflammation-inhibiting pathway of the copla-laparavone D is p-ERK, p-JNK, which is a type of mitogen activated protein kinase (MAPKs), p-JNK ethyl acetate = 10: 1 ratio solvent was used to obtain four fractions. Four fractions were separated by silica gel CC column chromatography using hexane: acetone = 5: 1, 4: 1, 3: 1, 2: . The third fraction was purified by silica gel CC column chromatography to obtain 65 mg of stepogensin using hexane: ethyl acetate = 3: 1 ratio solvent.
In order to identify the structure of the obtained steppogenin, 1 H-NMR of FIG. 8A and 13 C-NMR of FIG. 8B were used to identify the structure, and the results of FIG. 8C were obtained.
, p-38 pathway.
Example 2. Isolation of Steppogenin from Cucurbitaceae
A method of isolating steppogenin is shown in Fig. As shown in FIG. 1, 300 g of a 100% methanol extract was obtained by allowing the cucumber (6 kg) to stand at room temperature for 24 hours in 100% methanol. The 100% methanol extract was dissolved in water, and 160 g of a chloroform fraction was obtained using a solution-solution partitioning method using chloroform. The resulting chloroform fractions were fractionated using silica gel CC column chromatography (20%, 40%, 60%, 80%, 100% (v / v) EtOAc in hexane) . Fourth fraction (45 g) was purified by column chromatography on silica gel (C.
brown solid. 1 H-NMR (DMSO- d6, 400 MHz) δ 5.61 (dd, J = 2.8, 13.2 Hz, H-2), 3.25 (dd, J = 13.2, 17.2 Hz, H-3a), 2.62 (dd, J = 2.8, 17.2 Hz, H- 3b), 5.89 (br s, H-6, H-8), 6.37 (d, J = 1.6 Hz, H-3 '), 6.29 (d, J = 1.6, 8.4 Hz , H-5 '), 7.20 (d, J = 8.4 Hz, H-6'). 13 C-NMR (DMSO- d6, 100 MHz) δ 74.0 (C-2), 41.3 (C-3), 197.0 (C-4), 163.7 (C-5), 95.9 (C-6), 166.7 ( C-7), 95.1 (C-8), 163.6 (C-9), 101.9 (C-10), 115.6 158.8 (C-4 '), 106.7 (C-5'), 128.4 (C-6 ').
Experimental Example 6. Mouse-derived microglia, BV2 cell culture and cytotoxicity
Mouse microsomal BV2 cells (2 × 10 5 cells / well) were mixed with 10% heat-inactivated FBS, penicillin G (100 IU / ml, Gibco, 15240062) and streptomycin (100 μg / Gibco, 15240062), cultured in a 5
In order to measure cytotoxicity, mouse microglia BV2 cells were treated with 10, 20, 40, 80 μM steppogenin for 48 hours and cell viability was measured. When the steppogenin was treated at a concentration of 80 μM or less, The cell survival rate remained high regardless of the concentration of the genin (FIG. 9).
Experimental Example 7. Mouse-derived microglia BV2 In a cell Inhibitory effect of TNF-α, IL-1β, IL-12, and IL-6 mRNA on inflammatory cytokines
BV2 cells, a mouse-derived microglia, were treated with
Experimental Example 8. In BV2 cells, a mouse-derived microglia, inflammation mediators NO, PGE 2 , And iNOS and COX-2 protein expression inhibitory effect
In order to examine inhibition of protein expression of NO, PGE 2 , iNOS and COX- 2 , which are inflammatory mediators in BV2 cells of steppenin, Kim et al., European Journal of Pharmacology, 721, pp. 267-276, 2013) and western blot analysis (same method as Experimental Example 3).
As shown in FIG. 10, the increase in NO (FIG. 11A), the increase in PGE 2 (Fig. 11B), the effect of the step-dependent inhibition of steppenanin at 10, 20, 40, and 80 μM was confirmed. As a result, as shown in FIG. 11C, it was confirmed that the expression of iNOS and COX-2 protein, which are known as inflammatory mediators, is significantly suppressed as the concentration of stepogenin increases.
Experimental Example 9. Mouse-derived microglia in BV2 cells IκBα Decomposition inhibition, Iκ Bα phosphorylation inhibition, NFκB (p65, p50) Nucleus In addition, NFκB p65 Cohesion Inhibitory effect
The effects of stepojenin on NFκB-related pathways in BV2 cells were examined. Methods for the inhibition of IκBα decomposition, inhibition of IκBα phosphorylation, inhibition of NFκB p65 and p50 nuclear transfer, and inhibition of NFκB p65 binding ability were carried out by the method of Kim et al., European Journal of Pharmacology, 721, pp. 267-276, The experiment was carried out using western blot analysis, which is the same method as in Experimental Example 3.
BV2 cells were pretreated with 20, 40, and 80 μM stepepogenin for 3 hrs. After induction of the inflammatory response pathway with lipopolysaccharide, cells were cultured in a 5
Experimental Example 10. In mouse-derived microglia, BV2 cells, beauty Inhibitory effect of tolan-activated protein kinase expression
Expression of p-ERK, p-JNK, and p-38, which are mitogen-activated protein kinase (MAPKs), on lipopolysaccharide (LPS) -induced inflammatory response in BV2 cells of stepheninine In order to identify the inhibitory pathway, the method of Kim et al., European Journal of Pharmacology, 721, pp. 267-276, 2013 and Western blot analysis, which is the same method as in Experimental Example 3, Respectively.
BV2 cells were pretreated with 20, 40, and 80 μM of steppenine for 3 hours, and induced with inflammatory response by lipopolysaccharide, followed by culture in a 5
Claims (5)
The compound is obtained by extracting Curdrania tricuspidata with methanol; Dissolving the methanol extract in water and obtaining a chloroform fraction using a solution-solution dispensing method with chloroform; Wherein the chloroform fraction is separated through silica gel column chromatography to obtain fractions. The method according to claim 1, wherein the fraction is isolated through silica gel column chromatography. ≪ RTI ID = 0.0 > and / or < / RTI >
Wherein the inflammation-inhibiting pathway of the Cudraflavanone D or Steppogenin compound is characterized by inhibiting the p-JNK or p-38 pathway, wherein the pathogen is selected from the group consisting of Lou Gehrig's disease, Parkinson's disease, Huntington's disease, Alzheimer's disease , Multiple sclerosis, multiple nervous atrophy, epilepsy, encephalopathy, and stroke.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150106965A KR101672138B1 (en) | 2015-07-29 | 2015-07-29 | Composition comprising Cudraflavanone D or Steppogenin isolated from Cudrania tricuspidata as a standard for the preventing and treating of inflammatory diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150106965A KR101672138B1 (en) | 2015-07-29 | 2015-07-29 | Composition comprising Cudraflavanone D or Steppogenin isolated from Cudrania tricuspidata as a standard for the preventing and treating of inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101672138B1 true KR101672138B1 (en) | 2016-11-03 |
Family
ID=57571341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150106965A KR101672138B1 (en) | 2015-07-29 | 2015-07-29 | Composition comprising Cudraflavanone D or Steppogenin isolated from Cudrania tricuspidata as a standard for the preventing and treating of inflammatory diseases |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101672138B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190000086A (en) | 2017-06-22 | 2019-01-02 | 대구가톨릭대학교산학협력단 | Composition comprising compounds isolated from Morus alba for preventing or treating of inflammatory disease |
KR20200127424A (en) | 2019-05-02 | 2020-11-11 | 가천대학교 산학협력단 | A composition for preventing or treating Advanced Glycation Endproducts related diseases comprising extracts of Cudrania tricuspidata or compounds isolated therefrom |
KR20220020476A (en) | 2020-08-11 | 2022-02-21 | 극동대학교 산학협력단 | Composition comprising steppogenin for prevention or treatment of thrombotic disorders |
KR102563495B1 (en) * | 2022-08-19 | 2023-08-10 | 경북대학교 산학협력단 | A composition for preventing, alleviating, or treating cancer comprising steppogenin as an active ingredient |
-
2015
- 2015-07-29 KR KR1020150106965A patent/KR101672138B1/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
Bioorganic & Medicinal Chemistry Letters, 2006, vol. 16, pp. 5580~5583* |
Bioorganic & Medicinal Chemistry Letters, 2006, vol. 16, pp. 5580~5583* * |
Journal of Ethnopharmacology, 2013, vol. 149, pp. 169~175* * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190000086A (en) | 2017-06-22 | 2019-01-02 | 대구가톨릭대학교산학협력단 | Composition comprising compounds isolated from Morus alba for preventing or treating of inflammatory disease |
KR20200127424A (en) | 2019-05-02 | 2020-11-11 | 가천대학교 산학협력단 | A composition for preventing or treating Advanced Glycation Endproducts related diseases comprising extracts of Cudrania tricuspidata or compounds isolated therefrom |
KR20220020476A (en) | 2020-08-11 | 2022-02-21 | 극동대학교 산학협력단 | Composition comprising steppogenin for prevention or treatment of thrombotic disorders |
KR102563495B1 (en) * | 2022-08-19 | 2023-08-10 | 경북대학교 산학협력단 | A composition for preventing, alleviating, or treating cancer comprising steppogenin as an active ingredient |
WO2024039164A1 (en) * | 2022-08-19 | 2024-02-22 | 경북대학교 산학협력단 | Composition for preventing, ameliorating, or treating cancer comprising steppogenin as active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101672138B1 (en) | Composition comprising Cudraflavanone D or Steppogenin isolated from Cudrania tricuspidata as a standard for the preventing and treating of inflammatory diseases | |
US20220370407A1 (en) | Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound | |
KR102410619B1 (en) | A composition comprising the isolated compound 1 from an extract of alder tree for treating and preventing skeleton muscle-related disorder | |
KR101745338B1 (en) | Composition for preventing and treating inflammatory diseases comprising Sagassum serratifolium extract | |
EP2226077B1 (en) | Extract of Lycoris chejuenis and/or a compound isolated therefrom for preventing and/or treating a neurodegenerative disease | |
KR20120112137A (en) | Composition containing ethylacetate fraction of schisandra chinensis baillon or wuweizisu c isolated from the same for treating or preventing obesity | |
KR101449575B1 (en) | Composition comprising tenuifoliside A for preventing or treating inflammatory diseases | |
KR101355483B1 (en) | Pharmaceutical composition and functional food for preventing or treating neurodegenerative disease by Acorus gramineus extracts and Alpha-asarone as effective component | |
KR20190050674A (en) | Pharmaceutical composition for anti-inflammatory, and improvement of bone tissue generation or cartilage tissue generation comprising purified fraction materials from Stauntonia hexaphylla leaves or flavonoid compounds and caffeic acid compounds separated therefrom as active ingredients | |
KR102049875B1 (en) | Novel compounds derived from adventitious root cultures of Echinacea purpurea and anti-inflammatory use thereof | |
KR102059160B1 (en) | Composition for preventing or treating neurodegenerative diseases comprising daphnane or phobor diterpenoid compound | |
KR101850752B1 (en) | Composition for preventing and treating inflammatory diseases comprising Sagassum serratifolium extract | |
KR101996487B1 (en) | Medicinal composition and health functional food for preventing or treating inflammatory disease | |
KR101478487B1 (en) | Composition for treating prostate disease comprisng extract and hydrolysable Tannin from CLEYERA JAPONICA | |
KR20140132482A (en) | Food and pharmaceutical composition for preventing or improving cancer comprising extracts of Cinnamomum camphora Sieb. as effective component | |
KR102677572B1 (en) | A composition comprising an extract of Alpinia officinarum for treating and preventing skeleton muscle-related disorder | |
KR102502598B1 (en) | A composition for improving, preventing and treating of inflammatory or atopic dermatitis comprising Sargassum thunbergii extract | |
KR102219426B1 (en) | Anti-Metastasis Composition comprising Pufferfish Extract | |
KR102134389B1 (en) | New benzonitrile glycoside compounds and compositions for preventing or treating cancer comprising them | |
KR20240042861A (en) | Coumaroyl triterpene derivatives derived from Actinidia polygama and their use for preventing or treating diabetes | |
KR101908454B1 (en) | Composition for protecting neuronal cells comprising phenazine derivatives | |
KR20230161643A (en) | Anti-inflammatory composition comprising adventitious root extract of Abeliophyllum distichum as effective component | |
KR20220142700A (en) | Anti-inflammatory composition comprising fermented product of moringa oleifera lam | |
KR20230045772A (en) | Composition for improving, preventing or treating obesity with Ulmus parvifolia extract as an active ingredient | |
KR20230129313A (en) | Composition comprising extract of Pleurotus eryngii for anti-depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20191002 Year of fee payment: 4 |